1. Home
  2. BILL vs IRON Comparison

BILL vs IRON Comparison

Compare BILL & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

HOLD

Current Price

$47.88

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$82.54

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BILL
IRON
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.1B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
BILL
IRON
Price
$47.88
$82.54
Analyst Decision
Buy
Strong Buy
Analyst Count
21
11
Target Price
$57.90
$103.18
AVG Volume (30 Days)
2.6M
320.6K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,653,160,000.00
N/A
Revenue This Year
$14.18
N/A
Revenue Next Year
$13.83
$283.52
P/E Ratio
N/A
N/A
Revenue Growth
13.03
N/A
52 Week Low
$31.41
$40.00
52 Week High
$57.21
$99.50

Technical Indicators

Market Signals
Indicator
BILL
IRON
Relative Strength Index (RSI) 55.81 62.12
Support Level $46.72 $70.73
Resistance Level $49.60 $82.74
Average True Range (ATR) 2.04 2.94
MACD -0.45 0.05
Stochastic Oscillator 26.67 87.66

Price Performance

Historical Comparison
BILL
IRON

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: